Observational study of patients with systemic amyloidosis
Official title: Observational Epidemiological Study of Patients Suffering From Systemic Amyloidosis
Run by IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06866912 · Data updated 2026-11-12
This study looks at patients with systemic amyloidosis, especially those with heart issues, to learn more about their experiences and outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 99 Years |
| Sex | All |
| Enrollment | 750 (estimated) |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna Academic / other |
| Locations | 1 site (Bologna) |
| Status | Recruiting |
| Started | September 1, 2023 |
| Main results expected | August 31, 2033 |
| Study ends | August 31, 2033 |
| Registry record updated | March 10, 2025 |
| Trial ID | NCT06866912 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older diagnosed with amyloidosis or asymptomatic carriers of transthyretin gene mutations.
✕Probably not a fit
Patients who do not have amyloidosis or are under 18 years old may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational epidemiological study focuses on patients diagnosed with systemic amyloidosis, particularly those with cardiac involvement. It aims to gather data on the characteristics and outcomes of these patients to better understand the disease's impact. The study will include both symptomatic patients and asymptomatic carriers of mutations in the transthyretin gene, allowing for a comprehensive analysis of the condition. Participants will be recruited from a single institution in Bologna, Italy.
Why it matters
Potential benefit: If successful, this study could enhance understanding of systemic amyloidosis and improve patient management strategies.
How similar studies have gone: While observational studies on amyloidosis exist, this specific approach focusing on systemic amyloidosis and its cardiac implications may provide novel insights.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients diagnosed with amyloidosis or asymptomatic carriers of mutations in the transthyretin gene * minimum age of 18 years at the time of diagnosis * obtaining informed consent Exclusion Criteria: * nothing
Where it's running
-
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Italy Recruiting
Study contacts
- Principal investigator: Simone Longhi, MD — IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Study coordinator: simone longhi, MD
- Email: simone.longhi@aosp.bo.it
- Phone: 00390512149039
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
ATR 1072 in PRKAG2 Syndrome
A first-in-human study tests ATR 1072 to see if it is safe and how it behaves in adults with PRKAG2 Syndrome.
-
Modeling heart failure in Duchenne and Becker muscular dystrophy to find surrogate heart measures
This study will look at heart disease in people with Duchenne/Becker muscular dystrophy and carriers to see if MRI-based heart measures can predict death or major heart problems.
-
Multimodal Cardiac MRI to See How the Heart Is Working
This study tests a comprehensive MRI approach to characterize heart structure and tissue in adults with suspected or confirmed cardiovascular disease.
-
Genetic testing for AF-triggered cardiomyopathy
We will test whether people who develop heart failure during atrial fibrillation carry specific disease-causing gene variants compared with people who have AF but do not weaken their heart.
-
Mavacamten use and effectiveness in adults with obstructive hypertrophic cardiomyopathy in Japan
This project will see how well mavacamten works and how safe it is for adults in Japan with symptomatic obstructive hypertrophic cardiomyopathy who are receiving cibenzoline.
-
DMD gene changes and heart function in boys and young men with dystrophinopathies
This study will test whether specific DMD gene changes and routine heart tests (blood biomarkers, ECG, and echocardiography) can help identify early heart problems in boys and young men aged 2–24 with genetically confirmed dystrophinopathies.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.